Linked Life Data

10723507

Source:http://linkedlifedata.com/resource/pubmed/id/10723507

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2000-4-7
pubmed:abstractText
The current focus on simplifying treatment regimens for patients with human immunodeficiency virus (HIV) infection has contributed to the interest in once-daily therapy. The triphosphate of didanosine (2',3'-dideoxyinosine or DDI) has a long intracellular half-life, which supports the use of didanosine in a once-daily dosing schedule. Early clinical studies found that changes in surrogate markers were similar whether didanosine was dosed once or twice daily, while toxic effects occurred less frequently with once-daily dosing. Didanosine once-a-day used in combination with other drugs has also been studied, and results of some of these trials are summarized in this paper.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
1359-6535
pubmed:author
pubmed:issnType
Print
pubmed:volume
3 Suppl 4
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
35-7
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1998
pubmed:articleTitle
Didanosine once daily: an overview.
pubmed:affiliation
Royal Free Centre for HIV Medicine, Royal Free Hospital, Hampstead, London, UK. myoule@rfh1.demon.co.uk
pubmed:publicationType
Journal Article, Review